



# BREATH TESTS - PRINCIPLES, TECHNOLOGY AND APPLICATIONS




MUDr.Petr Kocha CSc.  
<http://gweb.zde.cz>



1.LF UK tutorial, July 2024



The clinical significance of exhaled air analysis is known since the time of Hippocrates. Ancient doctors knew that the smell of a patient's breath was associated with certain illnesses



bad breath	disease
fruity	diabetes
fish	kidneys
sour	asthma
sweet	liver cirrhosis
ammoniacal	kidneys
fecal	intestinal obstruction

*Recent Advances in Nanomaterial-Based Human Breath Analytical Technology for Clinical Diagnosis and the Way Forward.*  
*Kabir E, Raza N, Kumar V. et al. Chem. 2019; 5/12: 3020-3057*



**Non-invasive methods with the analysis of exhaled air offer very wide applications in clinical biochemistry, which are currently not sufficiently used. More than 8,500 publications are included in the NLM Pubmed database, and more than 40  $^{13}\text{C}$ -labeled substrates are described for methods with the stable carbon  $^{13}\text{C}$  isotope. With the development of new technologies, mass spectrometry analysis with selective, specific sensors based on nanochips, a higher use of non-invasive breath tests can perhaps be expected in the near future.**

**Stable carbon isotope breath tests $^{13}\text{C}$**

**Breath tests with hydrogen and methane**


**Analysis of nitric oxide in breath**

**Determination of alcohol and ketone in breath**

**Analysis of volatile organic compounds in breath**



## NLM - MEDLINE DATABASE ANALYSIS 1990 - 2023





## **<sup>13</sup>C BREATH TESTS IN GASTROENTEROLOGY**

### **ISOTOPE <sup>13</sup>C BENEFITS**

- <sup>13</sup>C**
- IS A STABLE ISOTOPE OF CARBON
  - IS NOT RADIOACTIVE
  - COMMON OCCURENCE IN THE NATURE
  - 1,1 % OF CARBON IN HUMAN BODY IS <sup>13</sup>C

### **ISOTOPE <sup>13</sup>C DISADVANTAGES**

- <sup>13</sup>C** - 1,1 % OF CARBON IN HUMAN BODY IS <sup>13</sup>C

## $^{13}\text{C}$ - BREATH TEST PRINCIPLE

Peroral administration

$^{13}\text{C}$ -substrate

enzymatic hydrolytic function GIT

$^{13}\text{C}$

absorption

Change in ratio  
 $^{13}\text{C}/^{12}\text{C}$   
after substrate administration

determination ratio  $^{13}\text{C}/^{12}\text{C}$

$^{13}\text{CO}_2$

elimination

$^{13}\text{C}$

matem. model

production  $\text{CO}_2$

DOB

hour output  
 $\text{CO}_2$

PDR

kinetics

PET

cummulative output  $\text{CO}_2$

cPDR



## 13C BREATH TESTS - RESULTS COUNTING

$\delta$  – DELTA,  $\delta$  is expressed in ‰ / per thousand

$$\delta \text{ (‰)} = (R_{\text{sample}}/R_{\text{standard}} - 1) \cdot 1000$$

$$\delta^{13}\text{C} \text{ (‰)} = ([^{13}\text{C}/^{12}\text{C}]_{\text{sample}}/[^{13}\text{C}/^{12}\text{C}]_{\text{standard}} - 1) \cdot 1000$$

DOB	Delta Over Baseline
PDR	Percent Dose Recover
cPDR	Cummulative Percent Dose Recovery
PET	Peak Excretion Time



## **$^{13}\text{C}$ BREATH TESTS - PDB STANDARD**

The PDB standard is the primary reference material for measuring natural changes in the content of the carbon isotope  $^{13}\text{C}$ , determined in calcium carbonate from shells Cretaceous belemnites of the genus *Belemnitella americana* from the Pee Dee geological formation in South Carolina (US)

PDB

Pee Dee Belemnitae

International standard  $^{13}\text{C} = 1.11237 \%$




## $^{13}\text{C}$ BREATH TESTS - PDB STANDARD

PDB - Pee Dee Belemnite *Belemnella americana*



## OCCURENCE $^{13}\text{C}$ IN NATURE




*13C abundances of nutrients and the effect of variations  
in 13C isotopic abundances of test meals formulated for  $^{13}\text{CO}_2$  breath tests.*  
Schoeller DA. et al.: Am J Clin Nutr. 1980; 33(11): 2375 - 2385



**HeliView - IRMS ANALYSER  
OF BREATH TESTS  
BASED ON CARBON  $^{13}\text{C}$**

## IRMS - BREATH TEST ANALYSER - DETECTION






## $^{13}\text{CO}_2$ ANALYSER WITH IR DETECTION



HeliFAN Plus  
IR spectrophotometr  
Fischer Analysen Instr.

## $^{13}\text{CO}_2$ ANALYSER WITH IR DETECTION



**OptoAcoustic detection**  
**Lehrer & Luft typ**  
**Lehrer E and Luft K F 1938**  
**German Patent No 730478**

- IR absorption
- pressure change
- membrane deformation
- acoustic signal



## HELICOBACTER PYLORI GUIDELINES

Statement 1: **UBT is the most investigated and best recommended non-invasive test in the context of a 'test-and-treat strategy'. Monoclonal SAT can also be used.** Serological tests can be used only after validation. Rapid ('office') serology tests using whole blood should be avoided in this regard.

Level of evidence: 2a Grade of recommendation: B

Statement 9: The available data consistently recognise **pepsinogen (Pg)** serology as the **most useful non-invasive test to explore the gastric mucosa status (non-atrophic vs atrophic)**. The PgI/PgII ratio can never be assumed as a biomarker of gastric neoplasia.

Level of evidence: 2a Grade of recommendation: A

*Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.*

*Malfertheiner P. et all. - The European Helicobacter Study Group (EHSG). Gut. 2017 Jan; 66 (1): 6-30*




## **$^{13}\text{C}$ -UREA BREATH TEST FOR HELICOBACTER PYLORI**


**SUBSTRATE:**  $^{13}\text{C}$ -UREA

**DOSAGE:** 50 - 100 mg

**TEST TIME:** 30 minutes



**global gastric test**



**local test - biopsy**




## **<sup>13</sup>C-UREA BREATH TEST FOR HELICOBACTER PYLORI**

**<sup>13</sup>C-UBT test, substrate - 75mg of labeled urea breath samples at T<sub>0</sub> and T<sub>30</sub> minutes DOB up to 4‰ Hp negative, above 5‰ Hp positive, if the result is 4-5‰, we recommend repeating the test**




**UBT - Hp INFAl  
registered in Czech - SÚKL**





## <sup>13</sup>C-UREA BREATH TEST FOR HELICOBACTER PYLORI



### CLINICAL RESULTS:

NUMBER OF UBT TESTS: 1621x

NEGATIVE RESULT: 1254x

POSITIVE RESULT: 333 x

GRAY SCALE 4 - 5: 36 x

**POSITIVITY – 20.5%**

### DETERMINATION OF HpSA IN FACES (HELICOBACTER STOOL ANTIGEN)

NUMBER OF HpSA TESTS: 1931x

NEGATIVE RESULT: 1678 x

POSITIVE RESULT: 253 x

**POSITIVITY – 13.1%**



## **$^{13}\text{C}$ - BREATH TESTS FOR PANCREATIC FUNCTION**

### **SUBSTRATE SELECTION**

- $^{13}\text{C}$  - TRIOLEIN
- $^{13}\text{C}$  - HIOLEIN
- $^{13}\text{C}$  - MIXED TRIGLYCERIDE
- $^{13}\text{C}$  - CHOLESTERYL OCTANOATE
- $^{13}\text{C}$  - TRIPALMITIN
- $^{13}\text{C}$  - TRIOCTANOIN
- $^{13}\text{C}$  - STARCH
- $^{13}\text{C}$  - BzTyrAla

**STEATORHEA  $> 11 - 14 \text{ g/day}$**   
**INTRALUMINAL LIPOLYSIS**  
**SPECIFICITY FOR PANCREATIC LIPASE**  
**LIPASE OUTPUT  $< 90 \text{ kU/hr}$**   
**PANCREAT. CHOLESTEROL ESTERASE**  
**STEATORHEA  $> 11 \text{ g/day}$**   
**FAT MALABSORPTION**  
**TISSUE DAMAGE, FIBROSIS  $> 30\%$**   
**AMYLASE SECRETION  $< 10\%$**   
**CORRELATION with the PABA test**



## EXOCRINE PANCREAS INSUFFICIENCY GUIDELINES

Which test is clinically indicated

**for diagnosing exocrine pancreatic insufficiency (PEI) ?**

**Statement 3-6.** In a clinical setting, a **non-invasive pancreatic function test (PFT) should be performed**. The **FE-1 test** is feasible and widely available and is therefore most frequently used in this setting, while the **13C mixed triglyceride breath test (13C-MTG-BT)** offers an alternative. The s-MRCP test may also be used as an indicator of PEI but provides only semiquantitative data.

(Grade 1B, agreement)

Is a pancreatic function test required for the diagnosis of CP?

**Statement 3-7. A function test is required for the diagnosis of CP.**

(Grade 2B, strong agreement)


Should a pancreatic function test be performed at the time of diagnosis?

**Statement 3-8. Every patient with a new diagnosis of CP**


should be screened for PEI. (Grade 1A, strong agreement)

## METABOLIC PROCESSES FOR $^{13}\text{C}$ -MTG BREATH TEST

PANCREATIC LIPASE



BREATH  $^{13}\text{CO}_2$




HEPATICAL  $\beta$  - OXIDATION



## **<sup>13</sup>C-MTG BREATH TEST FOR EXOCRINE PANCREATIC FUNCTION**

**<sup>13</sup>C-MTG test - in our arrangement we serve**  
**100 g of gluten-free bread with**  
**250 mg of mixed triglyceride in 20 g of margarine**  
**breath samples at time  $T_0$  to  $T_{360}$  minutes after 60 minutes**  
**cPDR<sub>6h</sub> pathological below 30% (BMR)**





## **<sup>13</sup>C-MTG BREATH TEST FOR EXOCRINE PANCREATIC FUNCTION**

**CLINICAL RESULTS:**

**NUMBER OF MTG TESTS: 407 x**

**NORMAL VALUE: 365 x**

**PATHOLOGICAL VALUE: 41 x**

**DETERMINATION OF PANCREATIC  
ELASTASE-1 IN FACES (FELA)**

**COMPLIANCE OF <sup>13</sup>C-MTG TEST WITH  
FELA 327 x - MATCH is 83%**

We recommend the determination of elastase-1 in the stool as a suitable static marker to assess the capacity of the exocrine pancreas, we suggest the <sup>13</sup>C-MTG breath test as a dynamic, functional test to assess the complex, digestive effect.



## **<sup>13</sup>C - BREATH TESTS FOR LIVER FUNCTIONS**

### **SUBSTRATE SELECTION**

- **<sup>13</sup>C - GALACTOSE**  
**CYTOSOL, PHOSPHORYLATION, DG.CIRRHOSIS**
- **<sup>13</sup>C - AMINOPYRINE**  
**CYP2C19, DEMETHYLATION, SEVERITY OF HCV FIBROSIS**
- **<sup>13</sup>C - PHENYLALANINE**  
**CYTOSOL, OXIDATION, FUNCTIONAL RESERVE ASSESSMENT**
- **<sup>13</sup>C - METHIONINE**  
**MITOCHONDRIA, OXIDATION, NAFLD ASSESSMENT**
- **<sup>13</sup>C - METHACETIN**  
**CYP1A2, DEMETHYLATION, LIVER DISEASE ASSESSMENT**

*Potential use of metabolic breath tests to assess liver disease and prognosis:  
has the time arrived for routine use in the clinic?*

Stravitz RT, Ilan Y. Liver Int. 2016 Oct 8. doi: 10.1111/liv.13268. [Epub]



## BREATH TEST WITH $^{13}\text{C}$ - METHACETIN



**Exalenz BreathID POCT analyzer**  
**continuous detection of the  $^{13}\text{C}/^{12}\text{C}$  ratio**  
**Molecular Correlation Spectroscopy (MCS)**  
**Clinical studies 2016-2019 with  $^{13}\text{C}$ -methacetin**  
**Non-alcoholic hepatitis (NASH, NAFLD),**  
**risk of cirrhosis in liver transplants**

**$^{13}\text{C}$  Methacatin - MBT analyzing liver function,  
can reliably predict liver decompensation  
in patients with compensated NASH cirrhosis.**


*The noninvasive point of care MBT accurately predicts decompensation events better than MELD in compensated ( $\text{MELD} < 15$ ) NASH cirrhotics.*

*Chalasani N, Lawitz E, Abdelmalek M. et al.,*

*AASLD Liver Meeting, San Francisco, November 2018, Abstract No.1337*




## BREATH TEST WITH $^{13}\text{C}$ - METHACETIN

LiMAX  $\mu\text{g/kg/hr}$ 

*Enzymatic liver function capacity correlates with disease severity of patients with liver cirrhosis: a study with the LiMAX test.*

Malinowski M, Jara M, Lüttgert K. et al. *Dig Dis Sci.* 2014 Dec;59(12):2983-2991


## BREATH TEST WITH $^{13}\text{C}$ - METHACETIN



**Assessment of liver function  
in real time**  
**2mg/kg  $^{13}\text{C}$ -methacetin i.v**  
**LiMAX score in mg/kg/hr**  
**10 patients with liver resection**

*First intraoperative measurement of liver functional capacity during liver surgery using the  $^{13}\text{C}$ -methacetin breath test: early results of a pilot study.*  
Makridis G, Oldhafer KJ. J Hepatobiliary Pancreat Sci. 2020; 27(5): 280-281


## <sup>13</sup>C-GLUCOSE BREATH TEST



Assessment of insulin resistance  
Dg. pre-diabetes and type 2 diabetes  
Insulin sensitivity index  
Patients: 31 NDC, 38 PD and 47 T2D  
75mg <sup>13</sup>C<sub>6</sub> D-glucose (<sup>13</sup>C-GBT)  
 $\text{ISI}_{120}$  is more sensitive than HOMA-IR

*Insulin sensitivity index (ISI<sub>0, 120</sub>) potentially linked to carbon isotopes of breath CO<sub>2</sub> for pre-diabetes and type 2 diabetes.* Ghosh C, Mukhopadhyay P, Ghosh S, Pradhan M. Sci Rep. 2015; 5: e11959

## <sup>13</sup>C-GLUCOSE BREATH TEST



*Investigation of Metabolism of Exogenous Glucose at the Early Stage and Onset of Diabetes Mellitus in Otsuka Long-Evans Tokushima Fatty Rats Using [1, 2, 3-<sup>13</sup>C]Glucose Breath Tests. Kawagoe N, Kano O, Kijima S, Tanaka H, Takayanagi M, Uruta Y. PLoS One. 2016; 11(8): e0160177*



## $^{13}\text{C}$ - BREATH TEST IN ACUTE MEDICINE



**Isomark Canary™ - BDV  $> 1.4\%$  accurately differentiates subjects with emerging infections and predicts the presence of infection up to 48 hours before clinical confirmation. BDV can predict the onset of infection and help distinguish SIRS from infection, which could prompt earlier diagnosis, earlier appropriate treatment, and improve outcomes.**

*Changes in exhaled  $^{13}\text{CO}_2/^{12}\text{CO}_2$  breath delta value as an early indicator of infection in intensive care unit patients. O'Rourke AP, Buckman SA, Evans DC, Kerwin AJ, Breunig EA, Bütz DE. J Trauma Acute Care Surg. 2019 Jan;86(1):71-78.*



## **$^{13}\text{C}$ -EBT - BREATH TEST FOR ALCOHOL BREAKDOWN**



### **$^{13}\text{C}$ -EBT - $^{13}\text{C}$ Ethanol Breath Test**

**the test substrate is  
100 ml of  $^{13}\text{C}$ -ethanol  
in 100 ml of Asahi beer  
polymorphism was tested  
alcohol dehydrogenase (ADH) a  
aldehyde dehydrogenase (ALDH)**

**Evaluation of alcohol metabolism in humans using the non-invasive [ $^{13}\text{C}$ ]-ethanol breath test – influence of gender, *Helicobacter pylori* infection and polymorphism of alcohol-oxidizing enzymes. Suzuki M, Tanaka S, Komatsu H, et al. Alimentary Pharmacology & Therapeutics 2006; 2: 177-181.**




Breath test	Indication	Sensitivity	Specificity
<sup>13</sup> C-Glykocholate	SIBO	76%	35%
<sup>13</sup> C-Xylose	SIBO	89%	30%
<sup>13</sup> C-Lactose	Malabsorption	84%	96%
<sup>13</sup> C-Urea	Hp infection	96%	93%
<sup>13</sup> C-Aminopyrin	Liver test	86%	68%
<sup>13</sup> C-Metacetin	Liver test	93%	94%
<sup>13</sup> C-Fenylalanin	Liver test	98%	60%
<sup>13</sup> C-Mixed-triglyceride	Pancreat.insufficiency	89%	81%
<sup>13</sup> C-Oktanoate	Gastric emptying	67%	80%

*Update on diagnostic value of breath test in gastrointestinal and liver diseases.*  
*Siddiqui I, Ahmed S, Abid S.*

*World J Gastrointest Pathophysiol.* 2016 Aug 15;7(3):256-265



## NATURAL SUBSTRATES WITH $^{13}\text{C}$ FOR BREATH TESTS



$^{13}\text{C}$ -enriched lactose, derived from milk of cows fed with silo corn ( $d = -10.885$ ) for 5 weeks.

Because it is known that it takes 14 days for cows milk to be in equilibrium with a diet, milk of seven cows was collected during the last 3 weeks of this 5-week period and pooled.

Lactose was obtained by crystallization techniques.



## NATURAL SUBSTRATES WITH $^{13}\text{C}$ FOR BREATH TESTS

J Gastroenterol Hepatol. 2005 Aug; 20(8): 1228 - 1234

Feasibility of a breath test with a substrate of natural  $^{13}\text{C}$ -abundance and isotope-selective non-dispersive infrared spectrometry: a preliminary study.

Jonderko K, Kasicka-Jonderko A, Syrkiewicz-Trepiaik D, Blonska-Fajrowska B.

Naturally  $(^{13}\text{C})$ -enriched starch and NDIRS provides background for future research on the clinical usefulness of this method for a non-invasive assessment of the pancreatic exocrine function.

J Lab Clin Med. 1988 Aug; 112(2): 193 - 200

$^{13}\text{CO}_2$  breath test using naturally  $^{13}\text{C}$ -enriched lactose for detection of lactase deficiency in patients with gastrointestinal symptoms.

Hiele M, Ghoos Y, Rutgeerts P, Vantrappen G, Carchon H, Eggermont E.

The  $^{13}\text{CO}_2$  breath test was found to be more sensitive (0.84 versus 0.68) and more specific (0.96 versus 0.89) than the  $\text{H}_2$  breath test in detecting low jejunal lactase activity.

The American Society for Nutritional Sciences J. Nutr. 134: 1193 - 1196, May 2004  
A Combined  $^{13}\text{CO}_2/\text{H}_2$  Breath Test Can Be Used to Assess Starch Digestion and Fermentation in Humans

Erin L. Symonds, Stamatiki Kritis, Taher I. Omari and Ross N. Butler

The  $^{13}\text{CO}_2/\text{H}_2$  breath test can be used to estimate digestion and fermentation of starches in different physiologic and pathologic conditions.



## **<sup>13</sup>C BREATH TESTS GUIDELINES - UEG**

This recommendation should improve pan-European harmonization of diagnostic approaches to symptoms and disorders that are very common in gastroenterology practice, both by specialists and primary care in both adult and pediatric patients.

In addition, this guide identifies areas for future clinical research involving the use of <sup>13</sup>C breath tests

**<sup>13</sup>C-UBT Urea Breath Test**

**<sup>13</sup>C GEBT Gastric Emptying Breath Tests**

**<sup>13</sup>C PFBT Pancreatic Function Breath Tests**

**<sup>13</sup>C MTGBT Mixed Triglyceride Breath Test**

**<sup>13</sup>C LFBT Liver Function Breath Tests**

*European guideline on indications, performance and clinical impact of <sup>13</sup>C-breath tests in adult and pediatric patients: An EAGEN, ESNM, and ESPGHAN consensus, supported by EPC. Keller J, Hammer HF, Afolabi PR et al. United European Gastroenterol J. 2021; 9: 598–625*



## **<sup>13</sup>C BREATH TESTS IN OTHER FIELDS OF MEDICINE**

*(<sup>13</sup>C)-tryptophan breath test detects increased catabolic turnover of tryptophan along the kynurenine pathway in patients with major depressive disorder.*  
*Teraishi T, Hori H, Sasayama D. et al. Sci Rep. 2015 Nov 3;5:15994.*

Our results suggest that the <sup>13</sup>C-TBT could be a novel biomarker for detecting a subgroup of MDD with increased tryptophan–KYN metabolism.

*<sup>13</sup>C-phenylalanine breath test detects altered phenylalanine kinetics in schizophrenia patients.* Teraishi T, Ozeki Y, Hori H. et al. *Transl Psychiatry.* 2012 May 22;2:e119


Our results suggest that <sup>13</sup>C-PBT is a novel laboratory test that can detect altered phenylalanine kinetics in chronic schizophrenia patients.

*A rapid non invasive L-DOPA-<sup>13</sup>C breath test for optimally suppressing extracerebral AADC enzyme activity - toward individualizing carbidopa therapy in Parkinson's disease.*  
*Modak A, Durso R, Josephs E. et al. J Parkinsons Dis. 2012;2(4):349-56.*

The LD-breath test can be a useful noninvasive diagnostic tool for evaluation of AADC enzyme activity using the biomarker <sup>13</sup>CO<sub>2</sub> in breath, a first step in personalizing CD doses for PD patients.




## HYDROGEN HAND ANALYZERS



H2 Check, MD Diagnostics

LactoFAN, FAN



**H<sub>2</sub> ANALYZERS ARE ESTABLISHED  
ON THE ELECTROCHEMICAL HYDROGEN DETECTOR  
AMPEROMETRIC (MICRO-FUEL))**



## WHY IS JUST HYDROGEN ANALYSIS NOT SUFFICIENT?

Gas	Amount
Hydrogen	H <sub>2</sub>
Methane	CH <sub>4</sub>
Carbon dioxide	CO <sub>2</sub>
Nitrogen	N <sub>2</sub>
Oxygen	O <sub>2</sub>

*Plyny v trávicím traktu, Lukáš K.  
Čes a Slov Gastroent a Hepatol 2009; 63(1): 20-24*

**Methane is produced by 24 - 48% population**

*Role of hydrogen and methane breath testing in gastrointestinal diseases  
Di Stefano M., Corazza GR. Dig. Liver Disease Suppl.3 (2009) 40–43*



## HOW BOWEL BACTERIA GENERATE GASES?


metanogenic bacteria




sulfat reducing bacteria



acetogenic bacteria



## WHY IS ANOTHER, THIRD ANALYST NEEDED?



INSPIRE-EXPIRE - NO HOLDING ONE'S BREATH

LOW CONC.CO<sub>2</sub>

INSPIRE-HOLD ONE'S BREATH SHORTLY - SHORT EXSPIRE

LOW CONC.CO<sub>2</sub>

INSPIRE-HOLD ONE'S BREATH FOR 10 S - LONG EXSPIRE

CONC.CO<sub>2</sub> IS OK



## WHY IS ANOTHER, THIRD ANALYST NEEDED?

If the alveolar air sample is contaminated with room air, the concentration of CO<sub>2</sub> in the sample will decrease, as will the other measured gases in the sample - H<sub>2</sub> and CH<sub>4</sub>

Correction factor = alveolar CO<sub>2</sub> concentration / sample CO<sub>2</sub> concentration

Correction factor set according to CO<sub>2</sub> concentration  
minimizes errors caused by incorrect sampling



## ALVEOLAR CO<sub>2</sub> CONCENTRATION

CO<sub>2</sub> is the physiological regulator of breathing, and the alveolar pressure pCO<sub>2</sub> is constant - 40 mm Hg (torr). Therefore, CO<sub>2</sub> is the most reliable "normalizer" of the measured gases in the sample.

Foreign studies show that the use of an alveolar concentration of 5.5% is suitable for calculating the correction factor

Alveolar pCO<sub>2</sub> is constant - 40 mm Hg. The percentage of CO<sub>2</sub> in alveolar air is affected by barometric pressure.

Alveolar air with a pCO<sub>2</sub> of 40 mm Hg, at sea level, will have a CO<sub>2</sub> concentration of about 5.5% while alveolar air in, say, Denver will have CO<sub>2</sub> of 6.8% (1610 m.a.s.l., barometric pressure is 625 torr)

## HYDROGEN / METHANE - LACTOTEST-202 XTEND





## HYDROGEN / METHANE BREATH TESTS

Breath test for SIBO, 75g glucose,

Breath samples are taken every 15 minutes for 3 hours

Breath test for lactose/fructose intolerance

20g lactose / 25g fructose

Breath samples are taken every 15 minutes for 4 hours

Test positivity – H<sub>2</sub>/CH<sub>4</sub> rise of 10ppm against basal value

### CLINICAL RESULTS:

NUMBER OF BREATH TESTS:

2300 x

SUSPECTED SIBO

80.4% of tests

**POSITIVITY – 39.3%**

SUSPECTED MALABSORPTION

19.6% of tests

**POCITIVITY – 55.0%**




## H<sub>2</sub> /CH<sub>4</sub> BREATH TESTS, INDICATIONS, RELIABILITY

Breath test	Indication	Sensitivity	Specificity
Glucoze HBT	SIBO	62%	83%
Lactulose HBT	SIBO	31%	86%
Fructose HBT	Malabsorption	98%	86%
Lactoze HBT	Malabsorption	80%	100%


*Update on diagnostic value of breath test in gastrointestinal and liver diseases.*  
*Siddiqui I, Ahmed S, Abid S.*

*World J Gastrointest Pathophysiol.* 2016 Aug 15;7(3):256-265


## H<sub>2</sub>/CH<sub>4</sub>/CO<sub>2</sub> - GLUCOSE TEST FOR SIBO



## H<sub>2</sub>/CH<sub>4</sub>/CO<sub>2</sub> - LACTOSE MALABSORPTION



## H<sub>2</sub>/CH<sub>4</sub>/CO<sub>2</sub> - LACTOSE MALABSORPTION + SIBO







## H<sub>2</sub>-FRUCTOSE BREATH TEST

Fructose breath test - 46-year-old patient L.S.

Breath test performed with fructose in doses of 25g, 10g and 5g during 6 weeks  
Samples taken every 4 hours and 15 minutes



## $^{13}\text{C}$ -ACETATE WITH $\text{H}_2$ -LACTULOSE BREATH TEST



*Simultaneous non-invasive measurement of liquid gastric emptying and small bowel transit by combined  $^{13}\text{C}$ -acetate and  $\text{H}_2$ -lactulose breath test.*  
 Bertram F, Andresen V, Layer P, Keller J. *J Breath Res.* 2014; 8(4): e046007

## DETECTION OF HYDROGEN, METHANE AND HYDROGEN SULFIDE

### HYDROGEN

Indicative of:  
**Small Intestinal Bacterial Overgrowth (SIBO)**

Correlated with:  
**No correlation with symptoms**

### METHANE

Indicative of:  
**Intestinal Methanogenic Overgrowth (IMO)**

Correlated with:  
**Constipation**



### HYDROGEN SULFIDE

Indicative of:  
**Excess Hydrogen Sulfide**

Correlated with:  
**Diarrhea**

**Trio-smart breath test**  
**PacificDx Lab in California**  
**Measuring H<sub>2</sub>, CH<sub>4</sub> a H<sub>2</sub>S**  
**Correction by CO<sub>2</sub>**  
**4-Gas Device**

*Validation of a 4-Gas Device for Breath Testing in the Determination of Small Intestinal Bacterial Overgrowth. Singer-Englar T, Rezaie A, Gupta K. et al. Gastroenterology, 2018, 154(6), s. 281*



## HYDROGEN BREATH TESTS GUIDELINES - UEG

This clinical practice recommendation should facilitate Europe-wide harmonization of diagnostic approaches to symptoms and disorders that are very common in specialist and primary care gastroenterology practice, both in adult and pediatric patients. In addition, it identifies areas of future research needs to clarify diagnostic and therapeutic approaches.

### **H<sub>2</sub>BT - Hydrogen Breath Tests**

**Small intestinal bacterial overgrowth - SIBO - glucose, lactulose**

**Oro-cecal transit time - OCTT - lactulose, inulin**

**Carbohydrate malabsorption:**

**Lactose malabsorption - lactose, Fructose malabsorption - fructose**

*European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients.*

*EAGEN, ESNM and ESPGHN consensus. Hammer HF, Fox MR, Keller J. et al.*

*United European Gastroenterol J. 2022; 10: 15-40.*




## ROUTINE ALCOHOL TEST – CLINICAL BENEFIT



A 37-year-old previously healthy man  
when entering service in a submarine  
routinely tested for alcohol  
**Diabetic ketoacidosis**  
a positive result of a manual breathalyzer

*Early Detection of Diabetic Ketoacidosis by Breathalyzer in a Sailor Reporting for Duty. Reinhart J. Mil Med. 2019; 184(11-12): e951-e952*

## ANALYSIS OF NITRIC OXIDE (FeNO) IN PNEUMOLOGY




COPD is a heterogeneous disorder with different phenotypes. The study is aimed at determining the prevalence of asthma history, peripheral eosinophilia and elevated FeNO levels, together with the diagnostic effectiveness of peripheral eosinophilia in identifying eosinophilic airway inflammation.

**FeNO**  
**Fractional exhaled Nitric Oxide**

*Eosinophilia and fractional exhaled nitric oxide levels in chronic obstructive lung disease. Annangi S, Nutalapati S, Sturgill J et al. Thorax. 2021 Aug 20. Epub. PMID: 34417353.*


## ANALYSIS OF NITRIC OXIDE (NO) IN GASTROENTEROLOGY




**NUD (Non Ulcer Dyspepsia) n=64**  
**PUD (Peptic Ulcer Disease) n=56**  
**Hp negative controls n=49**  
 $\Delta\text{NO}$  (ppb) detection CRDS  
**Cavity Ring-Down Spectroscopy**  
 $\delta^{13}\text{C} (< 3\%)$   $^{13}\text{C}$ -UBT detection ICOS  
**Laser-Based Integrated**  
**Cavity Output Spectroscopy**

*Exhaled nitric oxide as a potential marker for detecting non-ulcer dyspepsia and peptic ulcer disease. Som S, Dutta Banik G, Maity A et al. J Breath Res. 2018; 12(2): e026005*

## VOC - VOLATILE ORGANIC SUBSTANCES IN BREATH



*Investigation of different approaches for exhaled breath and tumor tissue analyses to identify lung cancer biomarkers. Gashimova E, Temerdashev A, Porkhanov V. et al. *Heliyon.* 2020; 6(6): e04224.*




*Assessment of breath volatile organic compounds in acute cardiorespiratory breathlessness: a protocol describing a prospective real-world observational study. Ibrahim W, Wilde M, Cordell R. BMJ Open. 2019; 9(3): e025486*



Acetone	diabetes, chronic kidney disease, lung CA
Acetaldehyde	CA breast
Formaldehyde	CA lung
Hexanol	CA lung
Octanol	Alzheimer's
Ethanol	liver steatosis, diabetes, CA lic
Ethylbenzene	Parkinson's, diabetes
Isoprene	chronic kidney disease, lung CA
Styrene	Alzheimer's, Parkinson's, chronic kidney disease, lung CA
Benzene	Alzheimer, Parkinson, TB, CRCA
Hexane	Alzheimer's, CA of the lungs, head and neck
Decane	Alzheimer, CA of the lungs, head and neck, breast and prostate
Octane	Alzheimer's, Parkinson's, chronic kidney disease, lung CA, head, neck

*Investigation of different approaches for exhaled breath and tumor tissue analyses to identify lung cancer biomarkers. Gashimova E, Temerdashev A, Porkhanov V. et al. Heliyon. 2020; 6(6): e04224.*

## ANALYSIS OF VOC IN PATIENTS WITH IBD



The study was conducted on VOC in exhaled air  
**Inflammatory Bowel Disease (IBD)**  
136 with Crohn's disease (CD)  
51 with ulcerative colitis (UC)  
Control - 14 healthy people  
Breath samples into Nalophan bags  
Mass spectrometry analysis  
with ion flow (SIFT-MS)

Pentane and other volatile organic compounds, including carboxylic acids, in the exhaled breath of patients with Crohn's disease and ulcerative colitis.  
Dryahina K, Smith D, Bortlik M. et al. J Breath Res. 2017; 12(1): e016002



## ARTIFICIAL INTELLIGENCE IN VOC ANALYSIS

**Study of 57 authors from 21 workplaces (Israel, France, USA)**

**Exhaled air samples of 1404 persons**

**A VOC 'breathprint' was defined for 17 diseases**

**lung cancer, colorectal cancer, ovarian cancer,  
prostate cancer, kidney cancer, stomach cancer,**

**head and neck cancer, bladder cancer,**

**Crohn's disease, ulcerative colitis, IBS,**


**Parkinson's disease, multiple sclerosis,**

**pulmonary arterial hypertension, pre-eclampsia, chronic renal failure**

**Reliability of artificial intelligence to diagnose 17 diseases is 86%**

***Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules. Nakhleh MK, Amal H, Jeries R. et al.***

***ACS Nano. 2017; 11(1): 112-125***



*Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules. Nakhleh MK, Amal H, Jeries R. et al. ACS Nano. 2017; 11(1): 112-125*



## BREATH BIOPSY – BREATH SAMPLING TECHNOLOGY



While blood, urine and stool tests became common ways disease identification, the development of breath tests faltered because it didn't exist yet reliable way breath sample collection and analysis.

*The Great Exhale Using Breath Analysis to Detect Disease.  
Mertz L.: IEEE Pulse. 2020; 11(3): 7-11*



<http://www1.lf1.cuni.cz/~kocna/glab/glency1.htm>

<http://gelab.zde.cz>

Skupina metodik funkce tenkého střeva, malabsorpce, screening célikie, střevní propustnost, bakteriální přerůstání

Anti-endomysium IgA  
Anti-gliadin IgA, IgG  
Anti-tTG IgA, IgG  
Anti-gliadin, tTG ve stolici  
A-vitamin zátežový test  
β-karoten  
β-karoten zátežový test  
Celiakie - screening  
Dechový test s laktózou  
Dechový test s xylózou  
Laktózový toleranční test  
Laktulózo/mannitolový test  
Xylózový toleranční test

Intro

Abecední přehled metodik

HON @ CODE CERTIFIED 02/2010

MINIENCYKLOPEDIJE LABORATORNICH METOD V GASTROENTEROLOGII

GastroLab

ASOCIACE AZ NA INTERNETU

Protilátky ke tkáňové transglutamináze (atTG) - IgA a IgG

**Tkáňová transglutamináza** má přímý vztah k patogenezi onemocnění a byla popsána jako vlastní, chemický substrát endomysia. Tkáňová transglutamináza - (isoenzym transglutaminasa II, TG2 - EC 2.3.2.13, je transferázou, systémový název je protein-glutamin:amin-g-glutamyltransferasa. Je to Ca<sup>2+</sup> dependentní enzym, katalyzující deaminaci glutamatu na glutamát, rovněž vede ke vzniku intramolekulární vazby glutamatu na další primární amin, např. lizin a vede k agregaci glutaminových peptidů. Stanovení protilátek ke tkáňové transglutamináze (atTG) má proto rovněž velmi vysokou diagnostickou efektivitu, podobně jako **EmA protilátky** (senzitivita 87-97% a specifita 88-98%). Stanovení atTG je prováděno klasickou metodou ELISA, což je pro rutinní diagnostiku technika dostupnější než immunofluorescenční průkaz EmA.

**Protilátky atTG** lze na rozdíl od EmA stanovovat ve třídě IgA i IgG, což má význam pro nemocné se selektivním deficitem IgA. Metoda byla popsána s použitím morčecího antigenu, který je použit ve většině starších souprav, novější soupravy již používají jako antigen tkáňovou transglutaminázu izolovanou z lidských buněk, z lidských erytrocytů, nebo rekombinantní tTG izolovanou na E. coli. Referenční hodnoty se liší u jednotlivých souprav, většinou je pro IgA protilátky uváděna horní hranice normy 10 - 15 IU/l, některé soupravy definují i tzv. gray-zone v rozsahu 10 - 20 IU/l. Stanovení protilátek atTG s lidským, rekombinantním antigenem vykazuje nižší falešnou pozitivitu než metody s morčecím antigenem. Nejnovější studie porovnávají protilátky třídy IgA a IgG, a POCT metodiky stanovení atTG protilátek. Stanovení protilátek atTG ve třídě IgA je doporučeno jako základní screeningový test pro diagnostiku **celiakie**. Pro screening byla v roce 2011 použita i technologie detekce atTG ve slinách, a nejnovější studie popisuje zcela nové technologie detekce protilátek elektrochemickými imunosenzory.

**Reference**

Volta U. - Gastroenterol Hepatol Bed Bench. 2023, Medline - link [PubMed](#)

Infantino M. - J Immunol Meth. 2021, Medline - link [PubMed](#)

Medline online latest publication

Direct link to MZČR National code

NČLP



**THANK YOU FOR**

**YOUR ATTENTION**